Psychedelic research trials with no phase
Data as of 10 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Phase not applicable is a registry phase value. The registry uses this value for studies that have no phase, such as many behavioural, observational or device studies. A phase describes how a study is designed, not what it found.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 97 registered studies are counted on this page.
Which substances
Counts per substance hub. Ketamine is limited to studies classified as psychiatric research, and records about disease-modifying therapy that match the abbreviation DMT are removed.
| Substance hub | Studies |
|---|---|
| Psilocybin | 15 |
| MDMA | 10 |
| LSD | 6 |
| DMT | 1 |
| Ayahuasca | 2 |
| Ketamine | 65 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 14 | 14% |
| Not yet recruiting | 4 | 4% |
| Enrolling by invitation | 3 | 3% |
| Active, not recruiting | 1 | 1% |
| Completed | 52 | 54% |
| Terminated | 4 | 4% |
| Suspended | 1 | 1% |
| Withdrawn | 3 | 3% |
| Status not reported | 15 | 15% |
Countries
Country is taken from the study's linked research site. 1 of 97 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 34 | 35% |
| Switzerland | 11 | 11% |
| Canada | 8 | 8% |
| China | 8 | 8% |
| United Kingdom | 8 | 8% |
| France | 6 | 6% |
| Austria | 3 | 3% |
| Brazil | 3 | 3% |
| Germany | 3 | 3% |
| Egypt | 2 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 37 |
| 2020 to 2023 | 23 |
| 2015 to 2019 | 12 |
| 2010 to 2014 | 21 |
| Before 2010 | 4 |
Study design
- 97 interventional and 0 observational studies.
- Median planned or actual enrolment is 35 participants (range 1 to 600, across 94 records that report it).
Topics named in study titles
A keyword match on registered titles, so one study can appear under more than one topic and a study can be missed. It describes what titles mention, nothing more.
| Topic | Studies |
|---|---|
| Depression and mood | 39 |
| Suicidal thoughts | 10 |
| Pain and headache | 3 |
| Trauma and PTSD | 2 |
| Alcohol use | 2 |
| Tobacco and nicotine | 1 |
| Other substance use | 1 |
| Obsessive-compulsive disorder | 1 |
Most recently started studies
The 25 studies with the latest start dates, newest first. The order is not a ranking. Each ID links to its own ClinicalTrials.gov record.
| Registry ID | Title as registered | Status | Phase | Country | Start |
|---|---|---|---|---|---|
| NCT07810023 | Intramuscular Ketamine for Suicidal Patients in the Evanston Hospital Emergency Department for Suicidal Distress | Enrolling by invitation | Not applicable | United States | 2026-09 |
| NCT07824973 | Ketamine Treatment for Treatment-Resistant Depression - the Role of Framing | Not yet recruiting | Not applicable | Sweden | 2026-09 |
| NCT07760740 | The Effect of Intraoperative Infusion of Esketamine on Cholestatic Pruritus in Patients Undergoing Hepatobiliary Surgery | Not yet recruiting | Not applicable | China | 2026-08 |
| NCT07737990 | Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression | Enrolling by invitation | Not applicable | Canada | 2026-07 |
| NCT07555132 | Circulating Oxytocin Changes in Response to MDMA vs. Placebo in Adult Patients With Autism Spectrum Disorder and Matched Healthy Controls | Not yet recruiting | Not applicable | Switzerland | 2026-06 |
| NCT07563868 | Coaching as an Adjunct to Ketamine Therapy for Treatment-Resistant Depression | Recruiting | Not applicable | United States | 2026-04 |
| NCT07396220 | Psychotherapy Combined With Intranasal Esketamine for the Treatment of Suicidal Ideation | Enrolling by invitation | Not applicable | United States | 2026-01 |
| NCT07309471 | Pharmacokinetics of Didehydro-LSD (DDH-LSD) Compared With LSD | Recruiting | Not applicable | Switzerland | 2026-01 |
| NCT07317219 | Ayahuasca, Esketamine and Body Image Perception | Recruiting | Not applicable | Brazil | 2025-12 |
| NCT07317232 | Ayahuasca, Esketamine and Premenstrual Symptoms | Recruiting | Not applicable | Brazil | 2025-12 |
| NCT07189299 | Microdosing LSD in Women With Premenstrual Disorders | Not yet recruiting | Not applicable | Switzerland | 2025-10 |
| NCT07422519 | Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression | Recruiting | Not applicable | Spain | 2025-09 |
| NCT06927076 | Antidepressant Response of DMT Masked With Propofol | Recruiting | Not applicable | Switzerland | 2025-08 |
| NCT07273851 | Comparison of Propofol and Ketofol as Induction Agents for Electroconvulsive Therapy | Completed | Not applicable | Panama | 2025-07 |
| NCT07526454 | Electroconvulsive Therapy Versus Intravenous Ketamine in Treatment-Resistant Major Depressive Disorder | Completed | Not applicable | Egypt | 2025-07 |
| NCT06620276 | ACT_for Alcohol Use Disorder and Depression | Recruiting | Not applicable | Canada | 2025-05 |
| NCT06789705 | Plasma Oxytocin Changes in Response to Low-dose MDMA vs. Placebo in Patients With Arginine Vasopressin Deficiency and Healthy Controls | Recruiting | Not applicable | Switzerland | 2025-01 |
| NCT06773143 | Effect of Subanesthetic Dose of Esketamine on Sleep Quality | Recruiting | Not applicable | China | 2024-12 |
| NCT06647056 | Evaluation of the Effect of a Single Dose of Psilocybin on Neural Correlates of Cognitive Control in Patients With Psychogenic Nonepileptic Seizures | Completed | Not applicable | France | 2024-12 |
| NCT06650800 | Effect of Psilocybin on the Positive Valence System in Treatment-resistant Depression | Completed | Not applicable | France | 2024-11 |
| NCT06526078 | Cognitive Training as an Adjunct to Ketamine in Real-world Clinics | Recruiting | Not applicable | United States | 2024-11 |
| NCT06529939 | The Effects of Psilocybin on Shared Experience in Film Processing | Status not reported | Not applicable | Canada | 2024-11 |
| NCT06560658 | Optimizing Microdosing and Meditation | Withdrawn | Not applicable | United States | 2024-10 |
| NCT07269964 | At-Home tDCS as Maintenance Therapy | Recruiting | Not applicable | Germany | 2024-10 |
| NCT06372197 | Low-Income Group Psilocybin Assisted Therapy for Depression | Completed | Not applicable | United States | 2024-08 |
Other substance hubs
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ayahuasca | Ketamine | Ibogaine
Registry status hubs
Recruiting | Not yet recruiting | Active, not recruiting | Enrolling by invitation | Completed | Terminated | Suspended | Withdrawn
Phase hubs
Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4